EUCTR2018-001201-93-ES进行中（未招募）1 期
Phase II study for the evaluation of neoadjuvant treatment with cabozantinib prior to cytoreductive nephrectomy in patients with locally advanced or metastatic renal cell carcinoma - CABOPRE
Fundación ONCOSUR0 个研究点目标入组 50 人开始时间: 2018年8月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must meet the following inclusion criteria:
- •1. Patients with locally advanced or metastatic renal cell carcinoma with a clear cell component confirmed histologically by biopsy.
- •2. Patients eligible for CN according to their surgical risk established in routine clinical practice at the center.
- •3. Age = 18 years.
- •4. Patients with an ECOG performance status of between 0 and 1.
- •5. Patients with appropriate organ and bone marrow function within 4 weeks prior to starting treatment with cabozantinib:
- •oLeukocyte count > 4,000 cells/µL
- •oHemoglobin > 9 g/dL
- •oPlatelet count > 100,000/mm3
- •oSerum creatinine < 2.0 mg/dL or serum creatinine clearance > 30 mL/min (according to the Cockcroft-Gault formula (Cockcroft and Gault 1976).
- •oPreserved liver function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN) in the absence of liver metastases; < 5 x ULN in the case of liver metastases.
- •oLipase < 2 x ULN. Amilase < 2 x LSN
- •oINR and APTT = 1.5 x ULN of the center. This only applies to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation with low molecular weight heparins should maintain stable doses.
- •6. Patients with no radiological or clinical evidence of pancreatitis.
- •7. Patients with evaluable tumor disease according to the RECIST criteria 1.1 (Eisenhauer et al. 2009).
- •8. Patients with controlled blood pressure (systolic < 145 mmHg; diastolic blood pressure < 90 mmHg).
- •9. Patients who sign informed consent to participate in the study.
- •10. Patients may have brain metastases appropriately treated with radiation therapy and/or surgery (including radiosurgery), as long as they do not require the concomitant use of corticosteroids.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •1. Patients with a second active malignant tumor.
- •2. Patients with tumors treated in the last 2 years.
- •3. Pregnant or breast-feeding women.
- •4. Women of child-bearing potential who do not agree to use a contraceptive method during treatment. Women participating in the study should have undergone surgical sterilization, be post-menopausal, or agree to use a highly effective contraceptive method (in accordance with CTFG criteria) during the treatment period. Both patients of both sexes and their partners must use effective contraception during treatment and, at least, up to four months after completing treatment. Since oral contraceptives can not possibly be considered effective contraceptive methods, they should be used in conjunction with another method, such as a barrier method.
- •5. Fertile men who do not agree to use a contraceptive method during treatment. Male participants in the study should have undergone surgical sterilization, or agree to use a highly effective contraceptive method (in accordance with CTFG criteria) during the treatment period.
- •6. Patients with gastrointestinal disorders, including:
- •oInability to take oral medication.
- •oNeed for parenteral nutrition.
- •oPrior surgical procedures affecting absorption.
- •oActive gastrointestinal bleeding.
- •oMalabsorption syndrome.
- •oGastrointestinal disorders that increase the risk of perforation.
- •7. Patients who have had any of the following conditions within the 12 months prior to inclusion in the study: myocardial infarction, uncontrolled angina, uncontrolled hypertension, peripheral arterial or coronary graft bypass, congestive heart failure, stroke, or transient ischemic attack.
- •8. Patients with tumors that invade or affect major blood vessels, gastrointestinal tract, or trachea/bronchi.
- •9. Patients with human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)-related diseases.
- •10. Patients with active hepatitis or hepatitis C.
- •11. Patients with active tuberculosis.
- •12. Patients with uncontrolled (Ca > 12 mg/dL) or symptomatic hypercalcemia who require continuous treatment with bisphosphonates or denosumab.
- •13. Patients who have undergone major surgery within 4 weeks prior to inclusion in the study.
- •14. Patients with active bleeding.
- •15. Patients with a recent episode of intestinal obstruction.
- •16. Patients who have previously received VEGF growth factor-targeted therapy for advanced disease.
- •17. Patients who have undergone radiation therapy for bone metastases within 2 weeks prior to the first dose of cabozantinib, or any external radiation therapy within 4 weeks prior to the first dose of cabozantinib.
- •18. Patients who have received an allogeneic transplant or stem cells in the last 5 years.
- •19. Malignant tumors within 3 years before Day 1 of Cycle 1, except for those with negligible risk of metastasis or death and who have been treated with curative intent, such as cervical carcinoma in situ or localized prostate cancer treated with curative intent.
- •20. Patients receiving therapeutic doses of oral anticoagulants (e.g., warfarin, direct thrombin inhibitors and Factor Xa) or antiplatelet agents (e.g., clopidogrel). The use of low molecular weight heparins is allowed.
- •21. Hypersensitivity to the active substance or to any of the excipients (exclude lactose intolerant patients since each film-coated tablet contains 46.61 mg of lactose)
- •22. Any other clinical condition that the physician responsible for the patient con
研究者
相似试验
进行中（未招募）
不适用
Phase II trial assessing neoadjuvant therapy with FEC 100 followed by Taxotere® (docetaxel) plus Vectibix® (panitumumab) in patients with operable, HR and Her-2 negative breast cancer. TVA study. - TVA studyRH- and Her2- operable breast cancer, in neoadjuvant situationMedDRA version: 9.1Level: LLTClassification code 10022882Term: Invasive ductal breast cancerEUCTR2009-012853-39-FRCentre Jean Perrin
进行中（未招募）
1 期
Phase II single-arm study evaluating abiraterone acetate (plus prednisolone) and Gonadotropin-Releasing Hormone (GnRH) agonist prior to receiving radical radiotherapy in high risk localised prostate carcinoma patientsHigh-risk prostate cancerMedDRA version: 20.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001128-31-IECancer Trials Ireland36
招募中
2 期
eoadjuvant DOS treatment for advanced esophageal cancerEsophageal cancerJPRN-jRCTs041210023Kodera Yasuhiro45
终止
2 期
Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells CancerRenal Cell Carcinoma MetastaticRenal Cell Carcinoma Stage IVRenal Cell Carcinoma Stage IIINCT06377722Fundacion Oncosur18
进行中（未招募）
1 期
Phase Ib/II study assessing the neo-adjuvant combination therapy of vinflunine with cisplatin followed by radical cystectomy in patients with muscle-invasive bladder cancerEUCTR2016-000081-33-DEigartis GmbH42